Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 14 November 2024 AM
A $151.4 million market is under threat after a judge ruled that a patent term extension granted in 2016 was not valid.
In June 2023 Novartis took Pharmacor to court, and was quickly granted an interlocutory injunction to prevent the generics company from moving ahead with plans to launch its generic version of Novartis' heart drug, Entresto.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.